Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Imatinib mesylate--a new oral targeted therapy.
Savage DG, Antman KH. Savage DG, et al. Among authors: antman kh. N Engl J Med. 2002 Feb 28;346(9):683-93. doi: 10.1056/NEJMra013339. N Engl J Med. 2002. PMID: 11870247 Review. No abstract available.
High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.
Papadopoulos KP, Garvin JH, Fetell M, Vahdat LT, Garrett TJ, Savage DG, Balmaceda C, Bruce J, Sisti M, Isaacson S, De LaPaz R, Hawks R, Bagiella E, Antman KH, Hesdorffer CS. Papadopoulos KP, et al. Among authors: antman kh. Bone Marrow Transplant. 1998 Oct;22(7):661-7. doi: 10.1038/sj.bmt.1701408. Bone Marrow Transplant. 1998. PMID: 9818693
A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk brain tumors.
Papadopoulos KP, Balmaceda C, Fetell M, Kaufman E, Vahdat LT, Bruce J, Sisti M, Isaacson S, De LaPaz R, Savage DG, Troxel A, Antman KH, Hesdorffer CS. Papadopoulos KP, et al. Among authors: antman kh. J Neurooncol. 1999 Sep;44(2):155-62. doi: 10.1023/a:1006391619009. J Neurooncol. 1999. PMID: 10619499 Clinical Trial.
Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT, Papadopoulos K, Balmaceda C, McGovern T, Dunleavy J, Kaufman E, Fung B, Garrett T, Savage D, Tiersten A, Ayello J, Bagiella E, Heitjan D, Antman K, Hesdorffer C. Vahdat LT, et al. Clin Cancer Res. 1998 Jul;4(7):1689-95. Clin Cancer Res. 1998. PMID: 9676843 Clinical Trial.
Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
Vahdat L, Papadopoulos K, Lange D, Leuin S, Kaufman E, Donovan D, Frederick D, Bagiella E, Tiersten A, Nichols G, Garrett T, Savage D, Antman K, Hesdorffer CS, Balmaceda C. Vahdat L, et al. Clin Cancer Res. 2001 May;7(5):1192-7. Clin Cancer Res. 2001. PMID: 11350883 Clinical Trial.
Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer.
Vahdat LT, Balmaceda C, Papadopoulos K, Frederick D, Donovan D, Sharpe E, Kaufman E, Savage D, Tiersten A, Nichols G, Haythe J, Troxel A, Antman K, Hesdorffer CS. Vahdat LT, et al. Bone Marrow Transplant. 2002 Aug;30(3):149-55. doi: 10.1038/sj.bmt.1703592. Bone Marrow Transplant. 2002. PMID: 12189532 Clinical Trial.
Kaposi's sarcoma.
Antman K, Chang Y. Antman K, et al. N Engl J Med. 2000 Apr 6;342(14):1027-38. doi: 10.1056/NEJM200004063421407. N Engl J Med. 2000. PMID: 10749966 Review. No abstract available.
193 results